MX2022005403A - Forma cristalina de base libre de un receptor del componente c5a de complemento. - Google Patents
Forma cristalina de base libre de un receptor del componente c5a de complemento.Info
- Publication number
- MX2022005403A MX2022005403A MX2022005403A MX2022005403A MX2022005403A MX 2022005403 A MX2022005403 A MX 2022005403A MX 2022005403 A MX2022005403 A MX 2022005403A MX 2022005403 A MX2022005403 A MX 2022005403A MX 2022005403 A MX2022005403 A MX 2022005403A
- Authority
- MX
- Mexico
- Prior art keywords
- free base
- receptor
- crystalline form
- complement component
- base crystalline
- Prior art date
Links
- 239000012458 free base Substances 0.000 title abstract 3
- 230000000295 complement effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010078546 Complement C5a Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932652P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/059287 WO2021092292A1 (en) | 2019-11-08 | 2020-11-06 | FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005403A true MX2022005403A (es) | 2022-05-24 |
Family
ID=75846182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005403A MX2022005403A (es) | 2019-11-08 | 2020-11-06 | Forma cristalina de base libre de un receptor del componente c5a de complemento. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11026935B2 (https=) |
| EP (1) | EP4054577A4 (https=) |
| JP (1) | JP2022554019A (https=) |
| KR (1) | KR20220098179A (https=) |
| CN (1) | CN114641289A (https=) |
| AU (1) | AU2020378061A1 (https=) |
| BR (1) | BR112022007488A2 (https=) |
| CA (1) | CA3155596A1 (https=) |
| CL (1) | CL2022001173A1 (https=) |
| IL (1) | IL292317A (https=) |
| MX (1) | MX2022005403A (https=) |
| WO (1) | WO2021092292A1 (https=) |
| ZA (1) | ZA202305622B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| JP2022554019A (ja) * | 2019-11-08 | 2022-12-27 | ケモセントリックス，インコーポレイティド | 補体成分Ｃ５ａ受容体の遊離塩基結晶形態 |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| JP7839157B2 (ja) * | 2020-10-28 | 2026-04-01 | ケモセントリックス， インコーポレイテッド | 化膿性汗腺炎を処置する方法 |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4996467B2 (ja) * | 2004-09-27 | 2012-08-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| DK3200791T3 (da) | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| CN114867473A (zh) * | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| JP2022554019A (ja) * | 2019-11-08 | 2022-12-27 | ケモセントリックス，インコーポレイティド | 補体成分Ｃ５ａ受容体の遊離塩基結晶形態 |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
-
2020
- 2020-11-06 JP JP2022525889A patent/JP2022554019A/ja not_active Withdrawn
- 2020-11-06 KR KR1020227018961A patent/KR20220098179A/ko not_active Withdrawn
- 2020-11-06 WO PCT/US2020/059287 patent/WO2021092292A1/en not_active Ceased
- 2020-11-06 MX MX2022005403A patent/MX2022005403A/es unknown
- 2020-11-06 CA CA3155596A patent/CA3155596A1/en active Pending
- 2020-11-06 EP EP20884944.8A patent/EP4054577A4/en not_active Withdrawn
- 2020-11-06 CN CN202080077446.8A patent/CN114641289A/zh active Pending
- 2020-11-06 AU AU2020378061A patent/AU2020378061A1/en not_active Abandoned
- 2020-11-06 IL IL292317A patent/IL292317A/en unknown
- 2020-11-06 BR BR112022007488A patent/BR112022007488A2/pt not_active IP Right Cessation
- 2020-11-06 US US17/091,019 patent/US11026935B2/en active Active
-
2021
- 2021-05-04 US US17/307,865 patent/US20220096453A1/en not_active Abandoned
-
2022
- 2022-05-04 CL CL2022001173A patent/CL2022001173A1/es unknown
-
2023
- 2023-04-24 US US18/305,611 patent/US20230381167A1/en not_active Abandoned
- 2023-05-25 ZA ZA2023/05622A patent/ZA202305622B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021092292A1 (en) | 2021-05-14 |
| US20210137907A1 (en) | 2021-05-13 |
| BR112022007488A2 (pt) | 2022-07-12 |
| EP4054577A1 (en) | 2022-09-14 |
| AU2020378061A1 (en) | 2022-05-26 |
| US20230381167A1 (en) | 2023-11-30 |
| JP2022554019A (ja) | 2022-12-27 |
| IL292317A (en) | 2022-06-01 |
| US11026935B2 (en) | 2021-06-08 |
| CL2022001173A1 (es) | 2023-02-10 |
| EP4054577A4 (en) | 2023-11-29 |
| US20220096453A1 (en) | 2022-03-31 |
| ZA202305622B (en) | 2024-01-31 |
| CN114641289A (zh) | 2022-06-17 |
| KR20220098179A (ko) | 2022-07-11 |
| CA3155596A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202305622B (en) | Free base crystalline form of a complement component c5a receptor | |
| ZA202305624B (en) | Amorphous form of a complement component c5a receptor | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| PH12020551821A1 (en) | Novel compounds | |
| PH12021550310A1 (en) | Novel sulfonamideurea compounds | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MX2024009540A (es) | Esteroides neuroactivos y composiciones de estos. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| PH12020500446A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| ZA202204442B (en) | Salt forms of a complement component c5a receptor | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| MX2021003232A (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2024015245A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX2020008982A (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico. | |
| WO2020049598A3 (en) | Apalutamide polymorphs | |
| MX2022011593A (es) | Formas cristalinas de un compuesto farmaceutico. | |
| PH12022551012A1 (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease |